Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Anafilaxia/prevención & control , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antineoplásicos Inmunológicos/uso terapéutico , Bevacizumab/uso terapéutico , Desensibilización Inmunológica/métodos , Hipersensibilidad a las Drogas/terapia , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Neoplasias Pulmonares/tratamiento farmacológico , Adenocarcinoma/complicaciones , Anafilaxia/etiología , Anticuerpos Monoclonales Humanizados/efectos adversos , Antineoplásicos Inmunológicos/efectos adversos , Bevacizumab/efectos adversos , Hipersensibilidad a las Drogas/complicaciones , Humanos , Neoplasias Pulmonares/complicaciones , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Resultado del TratamientoAsunto(s)
Anafilaxia/etiología , Anafilaxia/terapia , Antineoplásicos Inmunológicos/efectos adversos , Neoplasias de la Mama/complicaciones , Desensibilización Inmunológica , Trastuzumab/efectos adversos , Anafilaxia/diagnóstico , Antineoplásicos Inmunológicos/uso terapéutico , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/tratamiento farmacológico , Desensibilización Inmunológica/métodos , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/etiología , Hipersensibilidad a las Drogas/terapia , Femenino , Humanos , Persona de Mediana Edad , Terapia Molecular Dirigida/efectos adversos , Estadificación de Neoplasias , Pruebas Cutáneas , Evaluación de Síntomas , Trastuzumab/uso terapéuticoRESUMEN
Evidence that enables us to identify, assess, and access the small airways in asthma and chronic obstructive pulmonary disease (COPD) has led INTERASMA (Global Asthma Association) and WAO to take a position on the role of the small airways in these diseases. Starting from an extensive literature review, both organizations developed, discussed, and approved the manifesto, which was subsequently approved and endorsed by the chairs of ARIA and GA2LEN. The manifesto describes the evidence gathered to date and defines and proposes issues on small airway involvement and management in asthma and COPD with the aim of challenging assumptions, fostering commitment, and bringing about change. The small airways (defined as those with an internal diameter <2 mm) are involved in the pathogenesis of asthma and COPD and are the major determinant of airflow obstruction in these diseases. Various tests are available for the assessment of the small airways, and their results must be integrated to confirm a diagnosis of small airway dysfunction. In asthma and COPD, the small airways play a key role in attempts to achieve disease control and better outcomes. Small-particle inhaled formulations (defined as those that, owing to their size [usually <2 µm], ensure more extensive deposition in the lung periphery than large molecules) have proved beneficial in patients with asthma and COPD, especially those in whom small airway involvement is predominant. Functional and biological tools capable of accurately assessing the lung periphery and more intensive use of currently available tools are necessary. In patients with suspected COPD or asthma, small airway involvement must be assessed using currently available tools. In patients with subotpimal disease control and/or functional or biological signs of disease activity, the role of small airway involvement should be assessed and treatment tailored. Therefore, the choice between large- and small-particle inhaled formulations must reflect the physician's considerations of disease features, phenotype, and response to previous therapy. This article is being co-published in Asthma Research and Practice and the World Allergy Organization Journal.
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Adenocarcinoma/tratamiento farmacológico , Anafilaxia/prevención & control , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antineoplásicos/uso terapéutico , Bevacizumab/uso terapéutico , Desensibilización Inmunológica/métodos , Neoplasias Pulmonares/tratamiento farmacológico , Anafilaxia/inducido químicamente , Anticuerpos Monoclonales Humanizados/efectos adversos , Hipersensibilidad a las Drogas/terapia , Antineoplásicos/efectos adversos , Bevacizumab/efectos adversos , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
The inflammatory response in the upper airways secondary to viral or bacterial infection is frequent cause of medical attention and rhinosinusitis a common complication, changes in local and systemic immunity could facilitate the presence of sinusitis. Mediators derived from eosinophil could be also an important factor to develop nasal inflammation.
Asunto(s)
Rinitis/fisiopatología , Ribonucleasas , Sinusitis/fisiopatología , Proteínas Sanguíneas/análisis , Enfermedad Crónica , Proteínas en los Gránulos del Eosinófilo , Eosinofilia/fisiopatología , Humanos , Mucosa Nasal/inmunología , Senos Paranasales/fisiopatología , Infecciones del Sistema Respiratorio/complicaciones , Infecciones del Sistema Respiratorio/inmunología , Rinitis/etiología , Rinitis/inmunología , Rinitis Alérgica Perenne/inmunología , Rinitis Alérgica Perenne/fisiopatología , Sinusitis/etiología , Sinusitis/inmunologíaRESUMEN
We compared swab and scraping (Rhino-probe) technics in the nasal cytology obtention for eosinophils count in 36 patients with a range of 2-46 years old (mean age 18.6 years) with diagnosis of Allergic Rhinitis. The eosinophil count with swab technic was between 0-79 cells with average of 6.5 cells and in the scraping (Rhino-probe) was in a rate of 0-100 cells with a average of 13.4 cells. Of the 36 patients with Rhinitis seen at our clinic, 13 (36%) of positive with swab and 19 (53%) with scraping technics (Rhino-probe) with percent differential of 17%. The comparison between the eosinophils count with both technics was p less than 0.05 for scraping (Rhino-probe) technic.
Asunto(s)
Eosinófilos , Recuento de Leucocitos/métodos , Moco/citología , Rinitis Alérgica Perenne/patología , Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Recuento de Leucocitos/instrumentación , Masculino , Persona de Mediana Edad , Mucosa Nasal/patología , Rinitis Alérgica Perenne/inmunología , Manejo de EspecímenesRESUMEN
Chronic rhinosinusitis occurs to 5% of the population with upper respiratory infections. The objective of this study is to know the main symptoms in a pediatric population younger than 14 years with the diagnosis of chronic rhinosinusitis, to know age and sex distribution and evolution. We did a medical history, physical examination, nasal cytology, skin tests and sinus X rays in each of 100 patients. Results the main symptoms were: cough, halitosis, postnasal discharge, fever, headache, sore throat, facial sensitivity and periorbital edema. This findings predominated in males and the average evolution time was 1-2 years.